# Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

> **NCT05285891** · PHASE4 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 123 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab
- **DRUG:** Placebo for Ocrelizumab

## Key facts

- **NCT ID:** NCT05285891
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-12
- **Primary completion:** 2030-05-01
- **Final completion:** 2030-11-01
- **Target enrollment:** 123 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05285891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05285891, "Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05285891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*